Valion Bio, Inc. · NASDAQ:VBIO
Valion Bio — Tivic Health Systems — Investor Presentation (December 2022)
24 slides from Valion Bio's investor presentation, Dec 21, 2022
Slide 1: The future of medicine is electronic
Exhibit 99.1 TIWIC’ The future of medicine Is electronic. WSSU INVESTOR PRESENTATION TIvc 2022 DECEMBER ST@MP! CBS THIS Bit The inet [RACHAEL] sTowpwwy fg SESTHS Biinnoyrioy Ben
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS store fxs conse inthis presettn ma be fonacekrg statements tatements regarding our future results of operations and financial position, sconomie perfomance business strategy and plans and objectes of management for futur Cosas, eluding, aang oer, stems regarding ou exerted
Slide 3: Slide 3
Slide 4: Tivic Health Investment Highlights
TIVIC HEALTH Investment Highlights 2 FDA | Clearances P Commercial-stage company in high-growth, emerging market: + CE Mark Bioelectronic Medicine. & Built with vision to become a market leader in clinically validated, Projected to grow at 35% CAGR.! f $ 8 B YP FDA-approved, award-winning product in
Slide 5: The body is an electrochemical system
The body is an chemical.system. Bioelectronic medicine restores health by tuning body's innate electrical signals. Bioelectronic medicine represents a multi-billion-dollar opportunity and has the “potential to become a pillar of medical treatment.” McKinsey & Company
Slide 6: Bioelectronics Trajectory
BIOELECTRONICS TRAJECTORY “i Moving from Implants to Non-invasive Ce IMPLANTS NON-INVASIVE Boston, Scientific 1990s 2010s Deep Brain, Sleep Apnea Non-Invasive | Spinal Cord | _ Bioetectronics * Bioelectronics historically implanted technology. * Tivic Health tunes signals non-invasively. * Strong sa
Slide 7: Non-invasive Peripheral Nerve Stimulation
Non-invasive Peripheral Nerve Stimulation
Slide 8: Active Clinical Pipeline
Active Clinical Pipeline PRODUCT/ THERAPEUTIC DISCOVERY CLINICAL PIVOTAL REGULATORY COMMERCIAL PRODUCT LINE ‘AREA 7R&D FEASIBILITY STUDY. ~—- CLEARANCE —_ DISTRIBUTION us edcnetthn adults suffer Sinus Pain nasal allergies! 200M npdbex || Poet Operative > 600K US adults annually pus adults congestion
Slide 9: Clears Congestion, Relieves Sinus Pain
CLEARS CONGESTION, RELIEVES SINUS PAIN * FDA-approved and CE-marked OC * Proven in double-blind RCT @ (2) i No Drug Stanford Medical Center Side Effects ° $11.1B sinus, cold & allergy sector, ores dominated by pharmaceuticals! * 90% of sinus sufferers want to reduce use of pharmaceuticals Pulsed; lo
Slide 10: Market Landscape
MARKET LANDSCAPE $11.1B US Market in OTC Sinus Care Market ' by Daily Saline Irrigation Intranasal Steroids * Burning, stinging, nose * Oral and intranasal * Not effective for * Most commonly bleeds, headache, nausea, | * Insomnia, nervousness, congestion and pain recommended option for vomiting, di
Slide 11: Based on Science of Neuromodulation
BASED ON SCIENCE OF NEUROMODULATION Dual Mechanisms of Action Trigeminal More than a sinus treatment ClearUP has been proven effective in treating sinus and nasal jediates inflammatory conditions. pain relief * Other i atory ith nerve activity in Sympathetic the head andr neck represent. Seal produc
Slide 12: Clinical: Peer-Reviewed Publication
CLINICAL: PEER-REVIEWED PUBLICATION Fast-acting Double-blind, randomized, sham-controlled trial examined acute response. Reduction in pain and congestion, 10-minutes after first use. ® Stanford|mepicine Clinically meaningful reduction in pain and congestion 10 minutes after use. . Sham ClearuPy 8, C
Slide 13: Clinical: Peer-Reviewed Publication
CLINICAL: PEER-REVIEWED PUBLICATION Continued improvement with regular use 4-week open-label study showed continued reduction in pain and congestion ALLERGY ano. iN with daily use; also showed durable effect, relief present at 6 hours after treatment. ASTHMA ASSOCIATES Ja Continued week-over-week re
Slide 14: Robust Foundations
ROBUST FOUNDATIONS STRONG INTELLECTUAL PROPERTY Y ISSUED PATENTS 1 8 PATENTS PENDING Wd 96 issued claims THREE REGULATORY CLEARANCES | k182025 DEN200006 C € CE 704687 a PEER-REVIEWED PUBLICATIONS Double-blind, sham-controlled, randomized trial 3] Stanford|mepicine Published: International Forum of A
Slide 15: Market Size
MARKET SIZE 7 a Large Markets, Significant Growth Opportunity <ae/ ote oe OTC Sinus Care’ US Market. S ) By Nie: $8B “x US TAM { Peripheral nerve stimulation market forecast to grow at 35% CAGR. Allergy, Sinusitis, Cold & Flu, +
Slide 16: Market Development: Expanding The Growth Engine
MARKET DEVELOPMENT Expanding The Growth Engine 45M US adults suffer sinus pain fom allergies. 200M US adults suffer maderate to severe congestion Data from publicly avilable information combined with company Tive TIVICHEALTH.COM NASDAQ:
Slide 17: Market Development: Structured Approach to Growth
MARKET DEVELOPMENT Structured Approach to Growth 2022 202 024 Vi Product Harden and grow A Expand target New indications for b development 'Y ecommerce segments existing product platform Vv) FDA clearance Extend ClearUP. a New product platforms Market product line W1 introduction Controlled internat
Slide 18: Leadership Team
LEADERSHIP TEAM Experienced, Execution-oriented Leadership Jennifer Ernst Veronica Cai Blake Gurfein Ryan Sabia Chief Executive Officer, MBA pa founding to IPO in 5 years. Took prior and private company finance Ph.D. Neuroscientist, Asst. Prof. of Medicine, UCSF. Pfizer, EMD ‘Serono. Global sales, m
Slide 19: Financials
FINANCIALS ‘Twelve Months ‘Nine Months . 2020 - 2021 2021 - 2022 Operating Results a) ‘nrtors 18 40% 65% > nt Nine Months a E 14 Ended December 31 Ended September 30 iz | 12 (in thousands) FY 2021 FY 2020 | Interim 2022 Interim 2021 1.0 0.86 0.87 t os Revenues, $1,166 $860, -$ 1,432 $868 06 os Gross
Slide 20: Financials: Capitalization Table
FINANCIALS Capitalization Table December 15, 2022 Common Stock 9,677,734 Options (WAEP: $2.00) 1,268,850 Warrants (WAEP: $4.34) 272,680 Fully Diluted Shares 11,219,264
Slide 21: Financials: Financial Position
FINANCIALS Financial Position (in thousands) Cash and Cash Equivalents Total Assets Total Liabilities Total Stockholders’ Equity * Clean balance sheet ° No debt September 30, 2022 $ 6328 8,208 2,436 $ 5,772
Slide 22: Highlights: Investor Summary
HIGHLIGHTS Investor Summary Y FDA-cleared products in high-growth sector. Large available market $8B' in US; global opportunity. Established Tier 1 channels growing. Al Regulatory clearances for both US and international sales. vA Robust IP portfolio, recently issued patents. Clinical validation wit
Slide 23: Tivic Health Contact
TIWIC Jennifer Ernst CEO, Tivic Health ir@tivichealth.com naspag: TIVC TIVICHEALTH.COM
Slide 24: Appendix: Dual Mechanisms of Action
APPENDIX Dual Mechanisms of Action Trigeminal nerve mediates pain relief ‘Sympathetic nerves induce vasoconstriction 5 More than a sinus treatment ClearUP has been proven effective in treating * References for slide 11 footnotes: 1. Maul, Ximena A, etal. “Microcurent technology for rapid relief of s
Tivic Health Systems — Investor Presentation (December 2022) on 6ix